Qora71’s Post

🎙️ ASX Briefs Podcast    #Amplia CEO and MD Dr. Chris Burns spoke with ASX Briefs host Andrew Musgrave this week to discuss the Company's progress on the ACCENT trial investigating FAK-inhibitor narmafotinib in pancreatic cancer.     Dr. Burns discussed the growing prevalence of pancreatic cancer globally, and the urgent need for safe and efficacious treatments. He also shared the Company’s latest results from the Phase 2a trial, and the Company’s plans for the year ahead.     "We've just started recruiting our next 24 patients, and we'll finish that recruitment near the end of Q1 2025. At that point, we'll be releasing some early data from that clinical trial, that we think that will be quite interesting. Top line data will come out mid-year, and then a more complete data set by the end of 2025."     Listen here 👉 https://lnkd.in/gGeDHCjQ     $ATX #Amplia #innovation #biotech #pancreaticcancer #clinicaltrial #pharma

Exciting news! Our Business Development team is in Charlotte, North Carolina this week end to attend the AACR special conference on bladder cancer. If you're attending as well, be sure to stop by our booth to learn about how our cutting-edge #MIBC and #NMIBC models for preclinical oncology drug development. See you there! Discover more https://hubs.ly/Q02xFVXb0 #AACR2024 #BladderCancer #OncologyResearch #PreclinicalDrugDevelopment.

🎯 Out of the lab and into patients: targeting APE1/Ref-1 I had the privilege of speaking to Dr Mark R. Kelley, Associate Director of Basic Science at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center, and Betty and Earl Herr Professor in Pediatric Oncology Research, prior to his talk at American Association of Pharmaceutical Scientists (AAPS) | @aapscomms PharmSci360 in 2024. He elucidates what makes APE1/Ref-1 a promising target for cancer therapy, as well as promising preclinical data which indicates that other diseases could be addressed. Click on the link in the comments to read more! 👇 #cancer #preclinical #AAPS #PharmSci360

Proud to share a remarkable patient recovery story in Germany from our Compassionate Use program with Medias Klinikum. Faced with the dire prospect of a leg amputation due to an untreatable and inoperable sarcoma, the patient is now tumor-free, thanks to our innovative TumoCure treatment. IntraGel Therapeutics's cutting-edge approach involves a unique, honey-like gel, easily combined with most anti-cancer drugs and administered directly into the tumor via injection. This gel then solidifies, ensuring a controlled, prolonged release of the medication over weeks. This method not only maximizes therapeutic impact on the tumor but also significantly reduces severe side effects typically associated with cancer treatments. Intragel is paving the way for more effective, patient-friendly cancer care. #CancerTreatment #Innovation

Onchilles Pharma, a San Diego-based biotech company, presented promising preclinical data at the AACR annual meeting, showing a new molecule to be effective in treating all cancer types. Unlike other cancer treatments that target specific mutations, this molecule has variability and a nonspecific mechanism of action, making it unique. They plan to begin Phase 1 clinical trials later this year, after successfully testing the molecule on 60 different cancer types spanning 13 different anatomical locations. The first study is expected to show reductions in tumor size. For more on Onchilles' ground-breaking research, subscribe to SDBJ.com. https://lnkd.in/gR-rCQzE

The precision of LC-MS/MS is a game-changer in the development of antibody-drug conjugates (ADCs), essential for advancing oncology. By providing a detailed analysis of ADC components, LC-MS/MS ensures that new treatments are effective and safe for patients. Explore how this powerful analytical tool is paving the way for better cancer treatment outcomes. #CancerResearch #LCMS #ADCs #Biotechnology https://hubs.li/Q02GcTHJ0

Harnessing the power of Boron-10, drugs like Boronophenylalanine (BPA) are revolutionizing cancer treatment. Unlike other radiopharmaceuticals, BPA used in Boron Neutron Capture Therapy (BNCT) targets cancer cells with remarkable precision and 🌟 activated only🌟 when the patient is exposed to a beam of low-energy (epithermal) neutrons. The neutrons interact with the boron-10 atoms, producing high-energy alpha particles and lithium nuclei, effectively destroying cancer cells while sparing surrounding healthy tissue. This precise targeting and localized radiation damage make BNCT a promising, more effective, and less invasive treatment. Stay tuned for updates on how TAE Life Sciences and our novel Boron-10 drugs and BNCT are transforming oncology! 🧬 #CancerResearch #BNCT #Boron10 #OncologyInnovation #MedicalBreakthroughs

Several subsets of macrophage have been found to closely associate with metastasis-initiating cells in the tumor microenvironment >>> https://lnkd.in/ep_pE5q4 The authors hypothesize that the close spatial relationship of these high-risk cells and the macrophage subtypes could indicate that the macrophages play a role in metastasis and that they could even provide a new potential target for therapeutics, one day leading to interventions that could “change how neighborhoods of cancer cells are organized,” according to co-senior author Andrew Ewald.

Translational Drug Development (TD2) understands the nuances of Antibody Drug Conjugate (#ADC) development from the "Bench-to-Bedside." DM or email (mkoratich@td2inc.com) if you would like to learn more! #ADC #antibodydrugconjugate #cancertherapeutic #preclinical #regulatoryconsulting #ind #clinicaldevelopment #clinicaltrial #cro

"Antibody drug conjugates (ADCs) represent a significant advancement in cancer therapy, combining monoclonal antibodies with potent chemotherapeutic agents to precisely target and eliminate cancer cells." In our latest blog, Translational Drug Development (TD2) shares several key trends that are shaping the future of ADC development. Read it now: https://lnkd.in/gQ7pr2hQ